Industries > Pharma > Anti-neoplastic Agent Market Report to 2031
Anti-neoplastic Agent Market Report to 2031
By Type (Alkylating agents, Antimetabolites, Hormones and Antagonists, Miscellaneous, Others), by Application( Gastrointestinal Cancer, Prostate Cancer, Blood Cancer, Breast Cancer, Others), by End Users (Hospitals , Ambulatory surgical centers, Others) and Leading Regional/ Country market analysis
Anti-Neoplastic Agents Market– our new study reveals trends, R&D progress, and predicted revenues
Where is the Anti-Neoplastic Agents market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our Anti-Neoplastic Agents report provides tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Anti-Neoplastic Agents Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Anti-Neoplastic Agents Market by Type
• Alkylating agents
• Antimetabolites
• Hormones and Antagonists
• Miscellaneous.
Anti-Neoplastic Agents Market by Disease Type
• Gastrointestinal Cancer
• Prostate Cancer
• Lung Cancer
• Breast Cancer
• Others
Anti-Neoplastic AgentsMarket by End Users
• Hospitals
• Ambulatory surgical centers
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 16 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Japan
o Rest of Asia Pacific
• Latin America
o Rest of Latin America
• Middle East
o Rest of Middle East
The report also includes profiles and for some of the leading companies in the Anti-Neoplastic Agents Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Anti-Neoplastic Agents Market with forecasts for Type, Application and End-User, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Anti-Neoplastic Agents Market report helps you
In summary, our 268+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Anti-Neoplastic Agents Market, with forecasts for Type, Application, and End User, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Anti-Neoplastic Agentsmarket in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Rest of Asia Pacific, Latin America and Middle East and Africa among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for Anti-Neoplastic Agentsof the major companies involved in the Anti-Neoplastic Agents Market. Some of the company’s profiled in this report include-
• Pfizer Inc
• Merck & Co.
• Bayer AG
• Bristul-Myers Squibb Company
• Amgen Inc.
• Boehringer Ingelheim GmbH
• F. Hoffmann-La Roche Ltd
• Novartis
• Celgene Corporation
• Aspen Holdings
• Baxter Healthcare Corporation
• Teva pharmaceutical Industries Ltd
• Takeda
• Genentech Inc.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the global Anti-Neoplastic Agents Market and leading companies. You will find data, trends, and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Anti-neoplastic Agents Market Report to 2031: By Type (Alkylating agents, Antimetabolites, Hormones and Antagonists, Miscellaneous, Others), by Application( Gastrointestinal Cancer, Prostate Cancer, Blood Cancer, Breast Cancer, Others), by End Users (Hospitals , Ambulatory surgical centers, Others) and Leading Regional/ Country market analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Anti-Neoplastic Agents Market
2.1. Anti-Neoplastic Agents Market Definition
2.2. By Type Submarkets Definitions
2.3. By Application Submarkets Definitions
2.4. By End User Submarkets Definitions
3. Anti-Neoplastic Agents Market Overview
3.1. Global Anti-Neoplastic Agents Market Size and Forecast by Region
3.2. Global Anti-Neoplastic Agents Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising awareness and concern for diseases.
3.3.1.2. Growing demand for anti-neoplastic agents.
3.3.1.3. Rising incidence and prevalence of cancer.
3.3.2. Market Restraints/Challenges
3.3.2.1. High cost associated with R&D
3.3.2.2. Inadequate funding of healthcare in developing countries
3.3.3. Opportunities
3.3.3.1. Government initiative to promote prevention and control practices.
3.3.3.2. Increasing development of anti-neoplastic agents.
3.3.3.3. Growing health awareness among population
3.3.4. Global Anti-Neoplastic Agents Market: Trends
3.3.4.1. Growth in ageing population.
3.3.4.2. Advancement in healthcare sector.
3.3.5. Porter’s Five Forces Analysis
3.3.5.1. Competitive Rivalry
3.3.5.2. Supplier Power
3.3.5.3. Buyer Power
3.3.5.4. Threat of Substitution
3.3.5.5. Threat of New Entry
4. Global Anti-Neoplastic Agents Market Analysis and Forecast 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Alkylating agents
4.2.1.1. Busulfan, an alkyl sulfonate, is used to treat chronic myelocytic leukemia and polycythemia vera.
4.3. Antimetabolites
4.3.1.1. Methotrexate is widely used in the therapy of leukemia, lymphoma, solid tumors, psoriasis, and rheumatoid arthritis.
4.4. Hormones and Antagonists
4.4.1.1. Nilutamide is widely used in the therapy of prostate cancer.
4.5. Miscellaneous.
4.5.1.1. Eribulin mesylate is used for refractory, metastatic breast cancer and liposarcoma.
5. Global Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Gastrointestinal Cancer
5.1.1.1. Gastrointestinal cancer is most common and deadly neoplasms globally.
5.1.2. Prostate Cancer
5.1.2.1. Prevalence in developed countries.
5.1.3. Lung Cancer
5.1.3.1. Increasing incidence in developed countries, and high risk associated with elderly population.
5.1.4. Breast Cancer
5.1.4.1. Increasing number of new breast cancer cases.
5.1.5. Others
6. Global Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 by End User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Hospitals
6.1.1.1. Increasing hospitalization among elderly..
6.1.2. Ambulatory surgical centers
6.1.2.1. Rising adoption of Anti-Neoplastic Agents.
6.1.3. Others
7. North America Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Anti-Neoplastic Agents Market Size and Forecast By Type
7.2.1. Alkylating agents Submarket Expected to Grow at Significant Rate
7.3. North America Anti-Neoplastic Agents Market Size and Forecast By Application
7.3.1. Lung Cancer Submarket to Grow at Significant Rate
7.4. North America Anti-Neoplastic Agents Market Size and Forecast by End User
7.4.1. Hospitals Submarket to Grow at Significant Rate
7.5. U.S. Anti-Neoplastic Agents Market
7.5.1. High incidence of prostate cancer in the region.
7.6. Canada Anti-Neoplastic Agents Market
7.6.1. High incidence of women with lung cancer in the region.
8. Europe Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Anti-Neoplastic Agents Market Size and Forecast By Type
8.2.1. Alkylating agents Submarket Expected to Grow at Significant Rate
8.3. Europe Anti-Neoplastic Agents Market Size and Forecast By Application
8.3.1. Lung Cancer Submarket to Grow at Significant Rate
8.4. Europe Anti-Neoplastic Agents Market Size and Forecast by End User
8.4.1. Hospitals Submarket to Grow at Significant Rate
8.5. UK Anti-Neoplastic Agents Market
8.5.1. Increasing incidence of prostate cancer.
8.6. Germany Anti-Neoplastic Agents Market
8.6.1. Increasing preventive cancer programs.
8.7. France Anti-Neoplastic Agents Market
8.7.1. High expenditure on cancer drugs.
8.8. Rest of Europe Anti-Neoplastic Agents Market
9. Asia Pacific Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Anti-Neoplastic Agents Market Size and Forecast By Type
9.2.1. Alkylating agents Submarket Expected to Grow at Significant Rate
9.3. Asia Pacific Anti-Neoplastic Agents Market Size and Forecast By Application
9.3.1. Lung Cancer Submarket to Grow at Significant Rate
9.4. Asia Pacific Anti-Neoplastic Agents Market Size and Forecast by End User
9.4.1. Hospitals Submarket to Grow at Significant Rate
9.5. China Anti-Neoplastic Agents Market
9.5.1. Rising elderly population in the region.
9.6. India Anti-Neoplastic Agents Market
9.6.1. Increasing number of new cancer cases
9.7. Japan Anti-Neoplastic Agents Market
9.7.1. Change in lifestyle and tobacco smoking contributing to increase anti-neoplastic agent demand.
9.8. Rest of Asia Pacific Anti-Neoplastic Agents Market
10. Latin America Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Anti-Neoplastic Agents Market Size and Forecast By Type
10.2.1. Alkylating agents Submarket Expected to Grow at Significant Rate
10.3. Latin America Anti-Neoplastic Agents Market Size and Forecast By Application
10.3.1. Lung Cancer Submarket to Grow at Significant Rate
10.4. Latin America Anti-Neoplastic Agents Market Size and Forecast by End User
10.4.1. Brazil Anti-Neoplastic Agents Market
10.4.1.1. Limited access to proper diagnosis and treatment.
10.4.2. Mexico Anti-Neoplastic Agents Market
10.4.2.1. Breast cancer is the deadliest malignancy in Mexican women.
10.4.3. Rest of Latin America Anti-Neoplastic Agents Market
10.4.3.1. Increasing government initiatives.
11. MEA Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Anti-Neoplastic Agents Market Size and Forecast By Type
11.2.1. Alkylating agents Submarket Expected to Grow at Significant Rate
11.3. MEA Anti-Neoplastic Agents Market Size and Forecast By Application
11.3.1. Lung Cancer Submarket to Grow at Significant Rate
11.4. MEA Anti-Neoplastic Agents Market Size and Forecast by End User
11.5. South Africa Anti-Neoplastic Agents Market
11.5.1.1. Limited funding in the region.
11.6. Rest of MEA Anti-Neoplastic Agents Market
11.6.1.1. Increasingly healthcare awareness for diseases.
12. Companies in the Anti-Neoplastic Agents Market
12.1. Pfizer Inc.
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2020
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Merck & Co.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. Bayer AG
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Bristol-Myers Squibb Company
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. Roche Holding AG
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Amgen Inc.
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. Boehringer Ingelheim GmbH
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Novartis AG
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Celgene Corporation
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. AbbVie Inc.
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Anti-Neoplastic Agents Market Drivers & Restraints 2021
Table 7. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Antimetabolites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Antimetabolites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Antimetabolites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Antimetabolites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Antimetabolites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Hormones and Antagonists Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Hormones and Antagonists Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Hormones and Antagonists Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Hormones and Antagonists Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Hormones and Antagonists Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Miscellaneous Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Miscellaneous Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Miscellaneous Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Miscellaneous Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Miscellaneous Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Gastrointestinal Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Gastrointestinal Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Gastrointestinal Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Gastrointestinal Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Gastrointestinal Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Prostate Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Prostate Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Prostate Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Prostate Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Prostate Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Lung Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Lung Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Lung Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Lung Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Lung Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Breast Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Breast Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Breast Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Breast Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Breast Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 61. Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 62. Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 63. Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 64. Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 65. Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 66. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 67. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 68. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 69. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 70. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 71. Ambulatory surgical centers Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 72. Ambulatory surgical centers Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 73. Ambulatory surgical centers Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 74. Ambulatory surgical centers Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 75. Ambulatory surgical centers Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 76. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 77. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 78. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 79. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 80. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 81. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 82. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 83. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 84. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 85. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 86. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 87. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 88. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 89. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 90. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 91. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 92. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 93. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 94. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 95. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 96. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 97. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 98. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 99. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 100. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 101. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 102. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 103. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 104. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 105. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 106. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 107. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 108. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 109. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 110. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 111. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 112. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 113. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 114. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 115. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 116. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 117. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 118. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 119. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 120. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 121. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 122. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 123. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 124. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 125. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 126. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 127. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 128. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 129. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 130. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 131. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 132. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 133. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 134. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 135. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 136. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 137. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 138. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 139. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 140. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 141. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 142. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 143. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 144. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 145. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 146. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 147. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 148. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %CAGR %) (Before COVID)
Table 149. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %CAGR %), (COVID - Scenario W)
Table 150. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 151. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 152. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 153. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 154. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 155. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 156. Asia Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 157. Asia Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 158. Asia Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 159. Asia Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 160. Asia Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 161. Asia Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 162. Asia Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 163. Asia Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 164. Asia Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 165. Asia Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 166. Asia Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 167. Asia Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 168. Asia Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 169. Asia Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 170. Asia Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 171. Asia Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 172. Asia Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 173. Asia Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 174. Asia Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 175. Asia Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 176. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 177. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 178. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 179. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 180. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 181. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 182. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 183. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 184. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 185. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 186. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 187. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 188. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 189. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. RoAPAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. RoAPAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. RoAPAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. RoAPAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. RoAPAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209 Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. Middle East Anti-Neoplastic Agents Market Forecast By Application2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. Middle East Anti-Neoplastic Agents Market Forecast By Application2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216 Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217 Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233 Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236 Leading 10 Anti-Neoplastic Agents Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 237. Pfizer Inc Profile 2020 (CEO, HQ, Founded, Website)
Table 238. Pfizer Inc Anti-Neoplastic Agents Selected Recent Contracts 2020 (Date, Programme Type, Details)
Table 239. Pfizer Inc Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 240. Merck & Co. Profile 2020 (CEO, HQ, Founded, Website)
Table 241. Merck & Co Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 242. Bayer AG Profile 2020 (CEO, HQ, Founded, Website)
Table 243. Bayer AG Anti-Neoplastic Agents Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 244. Bayer AG. Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 245. Bristol-Myers Squibb Company Profile 2020 (CEO, HQ, Founded, Website)
Table 246. Bristol-Myers Squibb Company Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 247. Bristol-Myers Squibb Company Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 248. Roche Holding AG Profile 2020 (CEO, HQ, Founded, Website)
Table 249. Roche Holding AG Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 250. Amgen Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 251. Amgen Inc. Anti-Neoplastic Agents Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 252 Amgen Inc. Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 253. Boehringer Ingelheim GmbH Profile 2020 (CEO, HQ, Founded, Website)
Table 254. Boehringer Ingelheim GmbH Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 255. Boehringer Ingelheim GmbH Profile 2020 (CEO, HQ, Founded, Website)
Table 256. Boehringer Ingelheim GmbH Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 257. Novartis AG Profile 2020 (CEO, HQ, Founded, Website)
Table 258. Novartis AG Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 259. Celgene Corporation Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 260. Celgene Corporation Total Company Sales 2015-2019 (US$M, AGR %)
Table 261. Celgene Corporation Product Offering (Segment, Product Offerings)
Table 262. Other Companies Involved in the Anti-Neoplastic Agents Market (Company, Location)
LIST OF FIGURES
Figure 1. Anti-Neoplastic Agents Market Type Overview
Figure 2. Anti-Neoplastic Agents Market By Type Overview
Figure 3. Anti-Neoplastic Agents Market By Application Overview
Figure 4. Anti-Neoplastic Agents Market End User Overview
Figure 5 Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 16. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID – Scenario V)
Figure 17. Alkylating agents Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 18. Alkylating agents Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 19. Alkylating agents Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 20. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Lung Cancer Submarket Forecast 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 26. Lung Cancer Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario V)
Figure 27. Lung Cancer Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 28. Lung Cancer Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 29. Lung Cancer Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 30. Anti-Neoplastic Agents Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 31. Anti-Neoplastic Agents Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 32. Anti-Neoplastic Agents Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 33. Anti-Neoplastic Agents Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 34. Anti-Neoplastic Agents Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 35. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 36. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario V)
Figure 37. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 38. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 39. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 40. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure 41. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 42. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 43. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 44. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 45. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %)
Figure 51. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %)
Figure 56. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 61. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 62. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 63. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 64. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 65. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 66. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 67. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 68. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 69. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 70. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 71. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 72. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 73. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 74. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 75. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M)
Figure 76. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 77. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 78. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 79. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 80. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (Before COVID)
Figure 81. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 82. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 83. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 84. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 85. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (Before COVID)
Figure 86. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 87. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 88. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 89. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 90. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 91. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 92. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 93. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 94. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 95. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 98. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 101. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 102. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 103. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 104. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 105. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 106. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 107. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 108. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 109. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 110. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 111. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 112. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 113. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 114. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 115 Asia-Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (Before COVID)
Figure 116. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 117. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 118. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 119. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 120. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M)
Figure 121. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 122. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 123. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 124. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 125. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M)
Figure 126. Asia-Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 127. Asia-Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 128. Asia-Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 129. Asia-Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 130. Asia-Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Asia-Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 132. Asia-Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 133. Asia-Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 134. Asia-Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 135. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 136. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138 China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 141. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 142. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 143. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 144. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 145. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 146. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 147. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 148. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 149. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 150. Rest of APAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 151. Rest of APAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 152 Rest of APAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 153. Rest of APAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 154. Rest of APAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 155. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M)
Figure 156. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 157. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 158. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 159. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 160. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M)
Figure 161. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 162 Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M)
Figure 166. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Rest of Middle East Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 171. Rest of Middle East Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 172. Rest of Middle East Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 173. Rest of Middle East Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 174. Rest of Middle East Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 175. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M)
Figure 176. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 177. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 178. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 179. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 180. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M)
Figure 181. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 182. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 183. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 184. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 185. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M)
Figure 186. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 187. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 188. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 189. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 190. Rest of Latin America Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 191. Rest of Latin America Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 192. Rest of Latin America Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 193. Rest of Latin America Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 194. Rest of Latin America Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 195. Porter’s Five Force Analysis
Companies Mentioned
1. Pfizer Inc.
2. Merck & Co.
3. Bayer AG
4. Bristol-Myers Squibb Company
5. Roche Holding AG
6. Amgen Inc.
7. Boehringer Ingelheim GmbH
8. Novartis AG
9. Celgene Corporation
10. AbbVie Inc.
11. Eli Lilly
12. Aspen Holdings
13. Baxter Healthcare Corporation
14. Teva pharmaceutical Industries Ltd
15. Takeda
16. Genentech Inc.
17. Accord Healthcare, Inc.
18. Johnson & Johnson Pvt. Ltd.
19. Astellas
20. Biogen Idec
21. Sanofi
22. Teva
23. Otsuka
24. Merck KGaA
25. Ipsen
26. Gilead Sciences
27. Allergan
28. Novo Nordisk
29. GlaxoSmithKline Biologicals,
30. AstraZeneca PLC
31. Abbott Laboratories
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Anti-Neoplastic Agents Market
2.1. Anti-Neoplastic Agents Market Definition
2.2. By Type Submarkets Definitions
2.3. By Application Submarkets Definitions
2.4. By End User Submarkets Definitions
3. Anti-Neoplastic Agents Market Overview
3.1. Global Anti-Neoplastic Agents Market Size and Forecast by Region
3.2. Global Anti-Neoplastic Agents Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising awareness and concern for diseases.
3.3.1.2. Growing demand for anti-neoplastic agents.
3.3.1.3. Rising incidence and prevalence of cancer.
3.3.2. Market Restraints/Challenges
3.3.2.1. High cost associated with R&D
3.3.2.2. Inadequate funding of healthcare in developing countries
3.3.3. Opportunities
3.3.3.1. Government initiative to promote prevention and control practices.
3.3.3.2. Increasing development of anti-neoplastic agents.
3.3.3.3. Growing health awareness among population
3.3.4. Global Anti-Neoplastic Agents Market: Trends
3.3.4.1. Growth in ageing population.
3.3.4.2. Advancement in healthcare sector.
3.3.5. Porter’s Five Forces Analysis
3.3.5.1. Competitive Rivalry
3.3.5.2. Supplier Power
3.3.5.3. Buyer Power
3.3.5.4. Threat of Substitution
3.3.5.5. Threat of New Entry
4. Global Anti-Neoplastic Agents Market Analysis and Forecast 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Alkylating agents
4.2.1.1. Busulfan, an alkyl sulfonate, is used to treat chronic myelocytic leukemia and polycythemia vera.
4.3. Antimetabolites
4.3.1.1. Methotrexate is widely used in the therapy of leukemia, lymphoma, solid tumors, psoriasis, and rheumatoid arthritis.
4.4. Hormones and Antagonists
4.4.1.1. Nilutamide is widely used in the therapy of prostate cancer.
4.5. Miscellaneous.
4.5.1.1. Eribulin mesylate is used for refractory, metastatic breast cancer and liposarcoma.
5. Global Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Gastrointestinal Cancer
5.1.1.1. Gastrointestinal cancer is most common and deadly neoplasms globally.
5.1.2. Prostate Cancer
5.1.2.1. Prevalence in developed countries.
5.1.3. Lung Cancer
5.1.3.1. Increasing incidence in developed countries, and high risk associated with elderly population.
5.1.4. Breast Cancer
5.1.4.1. Increasing number of new breast cancer cases.
5.1.5. Others
6. Global Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 by End User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Hospitals
6.1.1.1. Increasing hospitalization among elderly..
6.1.2. Ambulatory surgical centers
6.1.2.1. Rising adoption of Anti-Neoplastic Agents.
6.1.3. Others
7. North America Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Anti-Neoplastic Agents Market Size and Forecast By Type
7.2.1. Alkylating agents Submarket Expected to Grow at Significant Rate
7.3. North America Anti-Neoplastic Agents Market Size and Forecast By Application
7.3.1. Lung Cancer Submarket to Grow at Significant Rate
7.4. North America Anti-Neoplastic Agents Market Size and Forecast by End User
7.4.1. Hospitals Submarket to Grow at Significant Rate
7.5. U.S. Anti-Neoplastic Agents Market
7.5.1. High incidence of prostate cancer in the region.
7.6. Canada Anti-Neoplastic Agents Market
7.6.1. High incidence of women with lung cancer in the region.
8. Europe Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Anti-Neoplastic Agents Market Size and Forecast By Type
8.2.1. Alkylating agents Submarket Expected to Grow at Significant Rate
8.3. Europe Anti-Neoplastic Agents Market Size and Forecast By Application
8.3.1. Lung Cancer Submarket to Grow at Significant Rate
8.4. Europe Anti-Neoplastic Agents Market Size and Forecast by End User
8.4.1. Hospitals Submarket to Grow at Significant Rate
8.5. UK Anti-Neoplastic Agents Market
8.5.1. Increasing incidence of prostate cancer.
8.6. Germany Anti-Neoplastic Agents Market
8.6.1. Increasing preventive cancer programs.
8.7. France Anti-Neoplastic Agents Market
8.7.1. High expenditure on cancer drugs.
8.8. Rest of Europe Anti-Neoplastic Agents Market
9. Asia Pacific Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Anti-Neoplastic Agents Market Size and Forecast By Type
9.2.1. Alkylating agents Submarket Expected to Grow at Significant Rate
9.3. Asia Pacific Anti-Neoplastic Agents Market Size and Forecast By Application
9.3.1. Lung Cancer Submarket to Grow at Significant Rate
9.4. Asia Pacific Anti-Neoplastic Agents Market Size and Forecast by End User
9.4.1. Hospitals Submarket to Grow at Significant Rate
9.5. China Anti-Neoplastic Agents Market
9.5.1. Rising elderly population in the region.
9.6. India Anti-Neoplastic Agents Market
9.6.1. Increasing number of new cancer cases
9.7. Japan Anti-Neoplastic Agents Market
9.7.1. Change in lifestyle and tobacco smoking contributing to increase anti-neoplastic agent demand.
9.8. Rest of Asia Pacific Anti-Neoplastic Agents Market
10. Latin America Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Anti-Neoplastic Agents Market Size and Forecast By Type
10.2.1. Alkylating agents Submarket Expected to Grow at Significant Rate
10.3. Latin America Anti-Neoplastic Agents Market Size and Forecast By Application
10.3.1. Lung Cancer Submarket to Grow at Significant Rate
10.4. Latin America Anti-Neoplastic Agents Market Size and Forecast by End User
10.4.1. Brazil Anti-Neoplastic Agents Market
10.4.1.1. Limited access to proper diagnosis and treatment.
10.4.2. Mexico Anti-Neoplastic Agents Market
10.4.2.1. Breast cancer is the deadliest malignancy in Mexican women.
10.4.3. Rest of Latin America Anti-Neoplastic Agents Market
10.4.3.1. Increasing government initiatives.
11. MEA Anti-Neoplastic Agents Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Anti-Neoplastic Agents Market Size and Forecast By Type
11.2.1. Alkylating agents Submarket Expected to Grow at Significant Rate
11.3. MEA Anti-Neoplastic Agents Market Size and Forecast By Application
11.3.1. Lung Cancer Submarket to Grow at Significant Rate
11.4. MEA Anti-Neoplastic Agents Market Size and Forecast by End User
11.5. South Africa Anti-Neoplastic Agents Market
11.5.1.1. Limited funding in the region.
11.6. Rest of MEA Anti-Neoplastic Agents Market
11.6.1.1. Increasingly healthcare awareness for diseases.
12. Companies in the Anti-Neoplastic Agents Market
12.1. Pfizer Inc.
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2020
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Merck & Co.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. Bayer AG
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Bristol-Myers Squibb Company
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. Roche Holding AG
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Amgen Inc.
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. Boehringer Ingelheim GmbH
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Novartis AG
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Celgene Corporation
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. AbbVie Inc.
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Anti-Neoplastic Agents Market Drivers & Restraints 2021
Table 7. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Antimetabolites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Antimetabolites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Antimetabolites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Antimetabolites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Antimetabolites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Hormones and Antagonists Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Hormones and Antagonists Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Hormones and Antagonists Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Hormones and Antagonists Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Hormones and Antagonists Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Miscellaneous Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Miscellaneous Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Miscellaneous Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Miscellaneous Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Miscellaneous Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Gastrointestinal Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Gastrointestinal Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Gastrointestinal Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Gastrointestinal Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Gastrointestinal Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Prostate Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Prostate Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Prostate Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Prostate Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Prostate Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Lung Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Lung Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Lung Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Lung Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Lung Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Breast Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Breast Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Breast Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Breast Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Breast Cancer Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 61. Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 62. Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 63. Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 64. Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 65. Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 66. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 67. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 68. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 69. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 70. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 71. Ambulatory surgical centers Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 72. Ambulatory surgical centers Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 73. Ambulatory surgical centers Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 74. Ambulatory surgical centers Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 75. Ambulatory surgical centers Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 76. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 77. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 78. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 79. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 80. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 81. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 82. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 83. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 84. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 85. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 86. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 87. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 88. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 89. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 90. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 91. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 92. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 93. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 94. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 95. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 96. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 97. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 98. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 99. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 100. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 101. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 102. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 103. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 104. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 105. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 106. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 107. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 108. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 109. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 110. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 111. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 112. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 113. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 114. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 115. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 116. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 117. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 118. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 119. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 120. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 121. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 122. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 123. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 124. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 125. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 126. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 127. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 128. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 129. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 130. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 131. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 132. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 133. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 134. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 135. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 136. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 137. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 138. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 139. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 140. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 141. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 142. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 143. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 144. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 145. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 146. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 147. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 148. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %CAGR %) (Before COVID)
Table 149. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %CAGR %), (COVID - Scenario W)
Table 150. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 151. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 152. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 153. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 154. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 155. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 156. Asia Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 157. Asia Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 158. Asia Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 159. Asia Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 160. Asia Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 161. Asia Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 162. Asia Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 163. Asia Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 164. Asia Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 165. Asia Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 166. Asia Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 167. Asia Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 168. Asia Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 169. Asia Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 170. Asia Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 171. Asia Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 172. Asia Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 173. Asia Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 174. Asia Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 175. Asia Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 176. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 177. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 178. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 179. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 180. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 181. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 182. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 183. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 184. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 185. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 186. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 187. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 188. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 189. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. RoAPAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. RoAPAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. RoAPAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. RoAPAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. RoAPAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209 Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. Middle East Anti-Neoplastic Agents Market Forecast By Application2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. Middle East Anti-Neoplastic Agents Market Forecast By Application2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216 Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217 Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233 Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236 Leading 10 Anti-Neoplastic Agents Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 237. Pfizer Inc Profile 2020 (CEO, HQ, Founded, Website)
Table 238. Pfizer Inc Anti-Neoplastic Agents Selected Recent Contracts 2020 (Date, Programme Type, Details)
Table 239. Pfizer Inc Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 240. Merck & Co. Profile 2020 (CEO, HQ, Founded, Website)
Table 241. Merck & Co Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 242. Bayer AG Profile 2020 (CEO, HQ, Founded, Website)
Table 243. Bayer AG Anti-Neoplastic Agents Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 244. Bayer AG. Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 245. Bristol-Myers Squibb Company Profile 2020 (CEO, HQ, Founded, Website)
Table 246. Bristol-Myers Squibb Company Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 247. Bristol-Myers Squibb Company Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 248. Roche Holding AG Profile 2020 (CEO, HQ, Founded, Website)
Table 249. Roche Holding AG Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 250. Amgen Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 251. Amgen Inc. Anti-Neoplastic Agents Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 252 Amgen Inc. Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 253. Boehringer Ingelheim GmbH Profile 2020 (CEO, HQ, Founded, Website)
Table 254. Boehringer Ingelheim GmbH Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 255. Boehringer Ingelheim GmbH Profile 2020 (CEO, HQ, Founded, Website)
Table 256. Boehringer Ingelheim GmbH Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 257. Novartis AG Profile 2020 (CEO, HQ, Founded, Website)
Table 258. Novartis AG Anti-Neoplastic Agents Product Offering (Segment, Product Offerings)
Table 259. Celgene Corporation Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 260. Celgene Corporation Total Company Sales 2015-2019 (US$M, AGR %)
Table 261. Celgene Corporation Product Offering (Segment, Product Offerings)
Table 262. Other Companies Involved in the Anti-Neoplastic Agents Market (Company, Location)
LIST OF FIGURES
Figure 1. Anti-Neoplastic Agents Market Type Overview
Figure 2. Anti-Neoplastic Agents Market By Type Overview
Figure 3. Anti-Neoplastic Agents Market By Application Overview
Figure 4. Anti-Neoplastic Agents Market End User Overview
Figure 5 Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Anti-Neoplastic Agents Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 16. Alkylating agents Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID – Scenario V)
Figure 17. Alkylating agents Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 18. Alkylating agents Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 19. Alkylating agents Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 20. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Anti-Neoplastic Agents Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Lung Cancer Submarket Forecast 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 26. Lung Cancer Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario V)
Figure 27. Lung Cancer Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 28. Lung Cancer Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 29. Lung Cancer Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 30. Anti-Neoplastic Agents Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 31. Anti-Neoplastic Agents Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 32. Anti-Neoplastic Agents Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 33. Anti-Neoplastic Agents Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 34. Anti-Neoplastic Agents Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 35. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 36. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario V)
Figure 37. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 38. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 39. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 40. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure 41. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 42. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 43. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 44. Regional Anti-Neoplastic Agents Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 45. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %)
Figure 51. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. North America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %)
Figure 56. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. North America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 61. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 62. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 63. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 64. North America Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 65. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 66. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 67. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 68. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 69. US Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 70. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 71. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 72. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 73. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 74. Canada Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 75. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M)
Figure 76. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 77. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 78. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 79. Europe Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 80. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (Before COVID)
Figure 81. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 82. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 83. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 84. Europe Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 85. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (Before COVID)
Figure 86. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 87. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 88. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 89. Europe Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 90. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 91. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 92. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 93. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 94. Europe Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 95. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 98. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. UK Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 101. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 102. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 103. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 104. Germany Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 105. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 106. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 107. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 108. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 109. France Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 110. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 111. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 112. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 113. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 114. Rest of Europe Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 115 Asia-Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (Before COVID)
Figure 116. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 117. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 118. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 119. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 120. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M)
Figure 121. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 122. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 123. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 124. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 125. Asia-Pacific Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M)
Figure 126. Asia-Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 127. Asia-Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 128. Asia-Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 129. Asia-Pacific Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 130. Asia-Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Asia-Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 132. Asia-Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 133. Asia-Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 134. Asia-Pacific Anti-Neoplastic Agents Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 135. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 136. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138 China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. China Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 141. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 142. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 143. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 144. India Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 145. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 146. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 147. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 148. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 149. Japan Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 150. Rest of APAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 151. Rest of APAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 152 Rest of APAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 153. Rest of APAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 154. Rest of APAC Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 155. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M)
Figure 156. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 157. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 158. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 159. Middle East Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 160. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M)
Figure 161. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 162 Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Middle East Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M)
Figure 166. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Middle East Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Rest of Middle East Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 171. Rest of Middle East Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 172. Rest of Middle East Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 173. Rest of Middle East Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 174. Rest of Middle East Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 175. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M)
Figure 176. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 177. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 178. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 179. Latin America Anti-Neoplastic Agents Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 180. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M)
Figure 181. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 182. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 183. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 184. Latin America Anti-Neoplastic Agents Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 185. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M)
Figure 186. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 187. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 188. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 189. Latin America Anti-Neoplastic Agents Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 190. Rest of Latin America Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %)
Figure 191. Rest of Latin America Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 192. Rest of Latin America Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 193. Rest of Latin America Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 194. Rest of Latin America Anti-Neoplastic Agents Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 195. Porter’s Five Force Analysis
Companies Mentioned
1. Pfizer Inc.
2. Merck & Co.
3. Bayer AG
4. Bristol-Myers Squibb Company
5. Roche Holding AG
6. Amgen Inc.
7. Boehringer Ingelheim GmbH
8. Novartis AG
9. Celgene Corporation
10. AbbVie Inc.
11. Eli Lilly
12. Aspen Holdings
13. Baxter Healthcare Corporation
14. Teva pharmaceutical Industries Ltd
15. Takeda
16. Genentech Inc.
17. Accord Healthcare, Inc.
18. Johnson & Johnson Pvt. Ltd.
19. Astellas
20. Biogen Idec
21. Sanofi
22. Teva
23. Otsuka
24. Merck KGaA
25. Ipsen
26. Gilead Sciences
27. Allergan
28. Novo Nordisk
29. GlaxoSmithKline Biologicals,
30. AstraZeneca PLC
31. Abbott Laboratories
Companies Profiled in the Report
1. Pfizer Inc
2. Merck & Co.
3. Bayer AG
4. Bristul-Myers Squibb Company
5. Roche Holding AG
6. Amgen Inc.
7. Boehringer Ingelheim GmbH
8. Novartis AG
9. Celgene Corporation
10. AbbVie Inc.
11. Eli Lilly
12. Aspen Holdings
13. Baxter Healthcare Corporation
14. Teva pharmaceutical Industries Ltd
15. Takeda
List of Companies Mentioned in the Report:
1. Pfizer Inc
2. Merck & Co.
3. Bayer AG
4. Bristul-Myers Squibb Company
5. Roche Holding AG
6. Amgen Inc.
7. Boehringer Ingelheim GmbH
8. Novartis AG
9. Celgene Corporation
10. AbbVie Inc.
11. Eli Lilly
12. Aspen Holdings
13. Baxter Healthcare Corporation
14. Teva pharmaceutical Industries Ltd
15. Takeda
16. Genentech Inc.
17. Accord Healthcare, Inc.
18. Johnson & Johnson Pvt. Ltd.
19. Astellas
20. Biogen Idec
21. Sanofi
22. Teva
23. Otsuka
24. Merck KGaA
25. Ipsen
26. Gilead Sciences
27. Allergan
28. Novo Nordisk
29. Teva Pharmaceutical Industries Ltd.
30. GlaxoSmithKline Biologicals,
31. AstraZeneca PLC
32. Abbott Laboratories
List of Organizations Mentioned in the Report
1. The Nemours Foundation
2. US Food & Drug Administration
3. US National Library of Medicine
4. National Institutes of Health
5. National Association for Biomedical Research
6. Center for Disease Control and Prevention CDC
7. US Center for Disease Control and Prevention
8. National Institute of Food and Agriculture (NIFA)
9. The Food & Agriculture Organisation
10. Center for Health Security
11. The History of Vaccines
12. Department of Medicine
13. National Cancer Institute
14. The Infectious Diseases Working Party (AGIHO)
15. Therapeutics in Dermatology
16. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
17. World Health Organisation
18. National Institute on Aging
19. National Institutes of Health
20. U.S. Department of Health and Human Services
21. United Nations world population
22. NCBI
23. Regulatory Affairs Professionals Society (RAPS)
24. American Cancer Society
25. The International Agency for Research on Cancer (IARC)
1. Pfizer Inc
2. Merck & Co.
3. Bayer AG
4. Bristul-Myers Squibb Company
5. Roche Holding AG
6. Amgen Inc.
7. Boehringer Ingelheim GmbH
8. Novartis AG
9. Celgene Corporation
10. AbbVie Inc.
11. Eli Lilly
12. Aspen Holdings
13. Baxter Healthcare Corporation
14. Teva pharmaceutical Industries Ltd
15. Takeda
List of Companies Mentioned in the Report:
1. Pfizer Inc
2. Merck & Co.
3. Bayer AG
4. Bristul-Myers Squibb Company
5. Roche Holding AG
6. Amgen Inc.
7. Boehringer Ingelheim GmbH
8. Novartis AG
9. Celgene Corporation
10. AbbVie Inc.
11. Eli Lilly
12. Aspen Holdings
13. Baxter Healthcare Corporation
14. Teva pharmaceutical Industries Ltd
15. Takeda
16. Genentech Inc.
17. Accord Healthcare, Inc.
18. Johnson & Johnson Pvt. Ltd.
19. Astellas
20. Biogen Idec
21. Sanofi
22. Teva
23. Otsuka
24. Merck KGaA
25. Ipsen
26. Gilead Sciences
27. Allergan
28. Novo Nordisk
29. Teva Pharmaceutical Industries Ltd.
30. GlaxoSmithKline Biologicals,
31. AstraZeneca PLC
32. Abbott Laboratories
List of Organizations Mentioned in the Report
1. The Nemours Foundation
2. US Food & Drug Administration
3. US National Library of Medicine
4. National Institutes of Health
5. National Association for Biomedical Research
6. Center for Disease Control and Prevention CDC
7. US Center for Disease Control and Prevention
8. National Institute of Food and Agriculture (NIFA)
9. The Food & Agriculture Organisation
10. Center for Health Security
11. The History of Vaccines
12. Department of Medicine
13. National Cancer Institute
14. The Infectious Diseases Working Party (AGIHO)
15. Therapeutics in Dermatology
16. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
17. World Health Organisation
18. National Institute on Aging
19. National Institutes of Health
20. U.S. Department of Health and Human Services
21. United Nations world population
22. NCBI
23. Regulatory Affairs Professionals Society (RAPS)
24. American Cancer Society
25. The International Agency for Research on Cancer (IARC)
Download sample pages
Complete the form below to download your free sample pages for Anti-neoplastic Agent Market Report to 2031Download sample pages
Complete the form below to download your free sample pages for Anti-neoplastic Agent Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
20 March 2023
Visiongain Publishes eClinical Solutions Market Report 2023-2033
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
17 March 2023
Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
15 March 2023
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.
10 March 2023
